Literature DB >> 11564857

The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis.

B Mograbi1, R Bocciardi, I Bourget, T Juhel, D Farahi-Far, G Romeo, I Ceccherini, B Rossi.   

Abstract

Hirschsprung's disease (HSCR), a frequent developmental defect of the enteric nervous system is due to loss-of-function mutations of RET, a receptor tyrosine kinase essential for the mediation of glial cell-derived neurotrophic factor (GDNF)-induced cell survival. Instead, gain-of-function Cys mutations (e.g., Cys(609), Cys(620), and Cys(634)) of the same gene are responsible for thyroid carcinoma (MEN2A/familial medullary thyroid carcinoma) by causing a covalent Ret dimerization, leading to ligand-independent activation of its tyrosine kinase. In this context, the association of Cys(609)- or Cys(620)-activating mutations with HSCR is still an unresolved paradox. To address this issue, we have compared these two mutants with the Cys(634) Ret variant, which has never been associated with HSCR, for their ability to rescue neuroectodermic cells (SK-N-MC cells) from apoptosis. We show here that despite their constitutively activated kinase, the mere expression of these three mutants does not allow cell rescue. Instead, we demonstrate that like the wild-type Ret, the Cys(634) Ret variant can trigger antiapoptotic pathways only in response to GDNF. In contrast, Cys(609) or Cys(620) mutations, which impair the terminal Ret glycosylation required for its insertion at the plasma membrane, abrogate GDNF-induced cell rescue. Taken together, these data support the idea that sensitivity to GDNF is the mandatory condition, even for constitutively activated Ret mutants, to rescue neuroectodermic cells from apoptosis. These findings may help clarify how a gain-of-function mutation can be associated with a developmental defect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564857      PMCID: PMC99850          DOI: 10.1128/MCB.21.20.6719-6730.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  58 in total

1.  Defects in enteric innervation and kidney development in mice lacking GDNF.

Authors:  J G Pichel; L Shen; H Z Sheng; A C Granholm; J Drago; A Grinberg; E J Lee; S P Huang; M Saarma; B J Hoffer; H Sariola; H Westphal
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

2.  Characterization of a multicomponent receptor for GDNF.

Authors:  J J Treanor; L Goodman; F de Sauvage; D M Stone; K T Poulsen; C D Beck; C Gray; M P Armanini; R A Pollock; F Hefti; H S Phillips; A Goddard; M W Moore; A Buj-Bello; A M Davies; N Asai; M Takahashi; R Vandlen; C E Henderson; A Rosenthal
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

3.  Functional receptor for GDNF encoded by the c-ret proto-oncogene.

Authors:  M Trupp; E Arenas; M Fainzilber; A S Nilsson; B A Sieber; M Grigoriou; C Kilkenny; E Salazar-Grueso; V Pachnis; U Arumäe
Journal:  Nature       Date:  1996-06-27       Impact factor: 49.962

4.  Renal agenesis and the absence of enteric neurons in mice lacking GDNF.

Authors:  M P Sánchez; I Silos-Santiago; J Frisén; B He; S A Lira; M Barbacid
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

5.  Renal and neuronal abnormalities in mice lacking GDNF.

Authors:  M W Moore; R D Klein; I Fariñas; H Sauer; M Armanini; H Phillips; L F Reichardt; A M Ryan; K Carver-Moore; A Rosenthal
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

Review 6.  RET mutations in human disease.

Authors:  B Pasini; I Ceccherini; G Romeo
Journal:  Trends Genet       Date:  1996-04       Impact factor: 11.639

7.  Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities.

Authors:  X Liu; Q C Vega; R A Decker; A Pandey; C A Worby; J E Dixon
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

8.  GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.

Authors:  S Jing; D Wen; Y Yu; P L Holst; Y Luo; M Fang; R Tamir; L Antonio; Z Hu; R Cupples; J C Louis; S Hu; B W Altrock; G M Fox
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

9.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

Authors:  H Donis-Keller; S Dou; D Chi; K M Carlson; K Toshima; T C Lairmore; J R Howe; J F Moley; P Goodfellow; S A Wells
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

10.  Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.

Authors:  T Iwashita; N Asai; H Murakami; M Matsuyama; M Takahashi
Journal:  Oncogene       Date:  1996-02-01       Impact factor: 9.867

View more
  5 in total

1.  Review.

Authors:  Sujal Rangwalla; Cheryl E Gariepy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

2.  Mutation of RET gene in Chinese patients with Hirschsprung's disease.

Authors:  Ji-Cheng Li; Shi-Ping Ding; Ying Song; Min-Ju Li
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

3.  Polymerase chain reaction-single strand conformational polymorphism analysis of rearranged during transfection proto-oncogene in Chinese familial Hirschsprung's disease.

Authors:  Tao Guan; Ji-Cheng Li; Min-Ju Li; Jin-Fa Tou
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

4.  The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease.

Authors:  Cristiana Carniti; Sara Belluco; Elena Riccardi; Aaron N Cranston; Piera Mondellini; Bruce A J Ponder; Eugenio Scanziani; Marco A Pierotti; Italia Bongarzone
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

Review 5.  Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2.

Authors:  Simona M Wagner; ShuJun Zhu; Adrian C Nicolescu; Lois M Mulligan
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.